Ожирение и остеопороз

Остеопороз и ожирение являются широко распространенными заболеваниями у людей после 50 лет и связаны с изменениями строения и состава тела. Эти болезни определяются как разными генетическими факторами, так и имеют в своей основе изменения общих клеток. С возрастом строение костного мозга изменяется в сторону преобладания адипоцитов, увеличения костно-резорбтивной активности и снижения образования остеобластов, что приводит к остеопорозу. Вторичные причины остеопороза, такие как сахарный диабет, гиперкортицизм, иммобилизация и метаболический синдром, ассоциируются с ожирением костного мозга. Изучение взаимосвязей между костью и жировой тканью на молекулярном и клеточном уровнях может привести к лучшему пониманию механизмов остеопороза и ожирения и разработке лекарств для лечения этих заболеваний.

1. Ожирение: этиология, патогенез, клинические аспекты. /Под ред. Дедова И.И., Мельниченко Г. А. - М.: ООО «Медицинское информационне агентство», 2006.

2. Остеопороз. Диагностика, профилактика и лечение.(клинические рекомендации) /Под ред. О.М. Лесняк, Л.И. Беневоленской. М.:ГЭОТАР - Медиа, 2009.

3. Проблема ожирения в Европейском регионе ВОЗ и стратегия ее решения. Резюме. ВОЗ. /Под ред. Branco F., Nikogosian H., Lobstein T. - Копенгаген, 2007.

4. Adler R.A., Rosen C.J. Glucocorticoids and osteoporosis . Endocrinol Metab Clin North Am 1994; 23: 641-54.

5. Ahdjoudj S., Lasmoles F., Holy X. et al. Transforming growth factor 2 inhibits adipocyte differentiation induced by skeletal unloading in rat bone marrow stroma. J Bone Miner Res 2002; 17(5): 668-77.

6. Akune T., Shinsuke O., Satoru K. et al. PPAR □ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004; 113(6): 846-55.

7. Ali A.A., Weinstein R.S,. Stewart S.A. et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinol 2005;146(3):1226-35.

8. Aubin J.E. Bone stem cells. J Cell Biochem 1998; Suppl 30-31: 73-82.

9. Balena R., Toolan B.C., Shea M. et al. The effects of 2-year treatment with the aminobisphosphonatealendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993; 92(6): 2577-86.

10. Botolin S., Faugere M-C., Malluche H. et al. Increased bone adiposity and peroxisomal proliferator-activated receptor- у 2 expression in type I diabetic mice. Endocrinology 2005; 146(8): 3622-31.

11. Burguera B., Hofbauer L.C., Thomas T. et al. Leptin reduces ovariectomy-induced bone loss in rats . Endocrinology 2001; 142(8): 3546-53.

12. Chavassieux P.M., Arlot M.E., Reda C. et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100(6):1475-80.

13. Cornish J., Callon K.E., Bava U. et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo . J Endocrinol 2002; 175: 405-15.

14. Dhillon H., Glatt V., Ferrari S.L. et al. Beta-adrenergic receptor KO mice have increased bone mass and strength but are not protected from ovariectomy-induced bone loss [abstract]. J Bone Miner Res 2004; 19 (Suppl 1): S32.

15. Ducy P. Amling M., Takeda S. et al . Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass . Cell 2000; 100(2): 197-207.

16. Duque G., Li W., Adams M. et al. Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporosis Int. 27 July 2010. DOI: 10.1007/s00198-010-1353-8.

17. Duque G., Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res. 2007; 22:1603-11.

18. Elbaz A., Wu X., Rivas D. et al. Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J. Cell. Mol. Med. 2010; 14(4): 982-91.

19. Elefteriou F., Ahn J.D. Takeda S. et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005; 434: 514-20.

20. Forsen L., Meyer H.E., Midthjell K. et al. Diabetes mellitus and then incidence of hip fracture results from the Nord-Trondelang Health Survey. Diabetologia 199; 42: 920-5.

21. Gilsanz V., Chalfant J., Mo A.O. et al. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J. Clin. Endocrinol. Metab. 2009; 94(9): 3387-93.

22. Gimble J.M., Robinson C.E., Wu X. et al. The function of adipocytes in the bone marrow stroma: an update. Bone 1996, 19(5): 421-8.

23. Gimble J.M., Zvonic S., Floyd Z.E. et al. Playing with bone and fat. J Cell Biochem. 2006; 98: 251-66.

24. Goulding A., Cannan R., Williams S.M. et al. Bone mineral density in girls with forearm fractures. J. Bone Miner. Res. 1998; 13(1): 143-8.

25. Hamrick M.W., Pennington C., Newton D. et al. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine . Bone 2004; 34: 376-83.

26. Haslam D.W. Obesity. Lancet 2005; 366: 1197-209.

27. Hsu Y. H. et al. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am. J. Clin. Nutr. 2006; 83: 146-54.

28. Im G.I., Qureshi S.A., Kenney J. et al. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004; 25:4105-15.

29. Johnell O., de Laet C., Johansson H. et al. Oral corticosteroids increase fracture risk independently of BMD. Osteoporos Int 2002;13(suppl 1): S14.

30. Justesen J., Stenderup K., Ebbesen E.N. et al. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001; 2(3): 165-71.

31. Kawai M., Rosen C.J. Bone: Adiposity and bone accrual-still an established paradigm? Nature Reviews Endocrinology 2010; 6: 63-4.

32. Khan A.W., Khan A. Anabolic agents: A new chapter in the management of osteoporosis. J Obstet Gynaecol Can. 2006; 28(2):136-41.

33. Li X, Jin L., Cui Q. et al. Steroid effects on osteogenesis through mesenchymal cell gene expression . Osteoporos Int 2005; 16: 101-8.

34. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-37.

35. Martin R.B., Zissimos S.L. Relationships between marrow fat and bone turnover in ovariectomized and intact rats. Bone 1991, 12(2): 123-31.

36. Meunier P., Aaron J., Edouard C., Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. Clin Orthop 1971;80:147-54.

37. Monami M., Cresci B., Colombini A., et al. Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients. Diabetes Care 2008, 31(2): 199-203.

38. Muhlen D., Safii S., Jassal S. K. et al. Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo study. Osteoporos. Int. 2007; 18: 1337-44.

39. Naganathan V., Jones G., Nash P. et al. Vertebral fracture risk with long-term corticosteroid therapy. Arch Intern Med 2000; 160:2917-22.

40. Nagasaki K., Kikuchi T., Hiura M. et al. Obese Japanese children have low bone mineral density after puberty. J. Bone Miner. Metab. 2004; 22: 376-81.

41. Nguyen N.D., Pongchaiyakul C., Center J.R. et al. Abdominal fat and hip fracture risk in the elderly: the Dubbo Osteoporosis Epidemiology Study. BMC Musculoskelet Disord. 2005; 6: 11-18.

42. Nicodemus K.K., Folsom A.R. Iowa women's health study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001; 24: 1192-7.

43. Okazaki R., Inoue D., Shibata M. et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology 2002; 143(6): 2349- 56.

44. Papakitsou E.F., Margioris A.N., Dretakis K.E. et al . Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women. Maturitas 2004; 47(3): 185-93.

45. Plotkin L.I., Aguirre J.I., Kousteni S. et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 2005; 280(8):7317-25.

46. Premaor M.O., Pilbrow L., Tonkin C. et al. Obesity and fractures in postmenopausal women. J. Bone and Mineral Research 2010; 25(2): 292-7.

47. Reid I.R. Leptin deficiency-lessons in regional differences in the regulation of bone mass. Bone 2004; 34: 369-71.

48. Reid I.R. Relationships among body mass, its components, and bone. Bone 2002; 31: 547-55.

49. Rodriguez J.P., Montecinos L., Rios S. et al. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J Cell Biochem 2000; 79(4): 557-65.

50. Rozman C., Feliu E., Berga L., et al. Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes: a stereological study. Exp Hematol 1989; 17(1): 34-7.

51. Russell R.G. Bisphosphonates: From bench to bedside. Ann N Y Acad Sci. 2006; 1068: 367-401.

52. Rzonca S.O., Suva L.J., Gaddy D. et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145(1): 401-6.

53. Schwartz A.V., Sellmeyer D.E., Ensrud K.E. et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001; 86: 32-8.

54. Sekiya I., Larson B. L., Vuoristo J. T. et al. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). J Bone Miner Res 2004; 19(2): 256-64.

55. Steppan C.M., Craword D.T., Chidsey-Frink K.L. et al. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000; 92(1-3): 73-8.

56. Still K., Phipps R.J., Scutt A. Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro. Calcif Tissue Int 2003; 72(2):143-50.

57. Sul H. S. Minireview: Pref-1: role in adipogenesis and mesenchymal cell fate. Mol. Endocrinol. 2009; 23: 1717-25.

58. Syed F.A, Oursler M.J., Hefferan T.E. et al. Effects of Estrogen Therapy on Bone Marrow Adipocytes in Postmenopausal Osteoporotic Women. Osteoporos Int. 2008; 19(9): 1323-30.

59. Takeda S., Elefteriou F., Levasseur R. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111(3): 305-17. 18

60. The living skeleton. /Ed. Ch. Roux. Wolters Kluwer Health, 2007.

61. Tuominen J.T., Impivaara O., Puukka P. et al. Bone mineral density in patients with type 1 and type 2 diabetes . Diabetes Care 1999; 22: 1196-200.

62. Uchiyama Y., Miyama K., Kataginri T. et al. Adipose conversion is accelerated in bone marrow cells of congenitally osteoporotic SAMP6 mice [abstract]. J Bone Miner Res 1994; 9(Suppl 1): S321.

63. Verma S., Rajaratnam J.H., Denton J. et al. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 2002; 55(9): 693-8.

64. Van Staa T., Leufkens H.G.M., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.

65. Von Mach M.A., Stoeckli R., Bilz S. Et al. Changes in bone mineral content after surgical treatment of morbid obesity. Metabolism 2004; 53(7): 918-21.

66. Wang M.C., Bachrach L.K., Van Loan M. et al. The relative contributions of lean tissue mass and fat mass to bone density in young women. Bone 2005; 37(4): 474-81.

67. Wehrli F.W., Hopkins J.A., Hwang S.N., et al. Cross-sectional study of osteopenia with quantitative MR imaging and bone densitometry. Radiology 2000; 217: 527-38.

68. Weisberg S.P., McCann D., Desai M. et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112(12): 1796-1808.

69. Zhao L.J., Jiang H., Papasianm Ch.J. et al. Correlation on obesity and osteoporosis : effect of fat mass on the determination of osteoporosis. J Bone Miner Res 2008; 23(1): 17-29.